PLASMACYTOMA

Clinical trials for PLASMACYTOMA explained in plain language.

Never miss a new study

Get alerted when new PLASMACYTOMA trials appear

Sign up with your email to follow new studies for PLASMACYTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Terminated 1

New hope for Tough-to-Treat blood cancer?

Disease control Terminated

This early-stage study tested a new drug, KRT-232, added to a standard three-drug combination for multiple myeloma that has come back or stopped responding to treatment. The main goals were to find the safest dose and see how well the body handles the four-drug combination. It in…

Matched conditions: PLASMACYTOMA

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 16, 2026 15:26 UTC

PLASMACYTOMA

Get alerted when new PLASMACYTOMA trials appear

New hope for Tough-to-Treat blood cancer?